Back to search

FORNY20-FORNY2020

BioClean: et nytt instrument for behandling av tannimplantat relatert sykdom

Alternative title: BioClean: A new instrument for maintenance treatment of peri-implant disease

Awarded: NOK 1.7 mill.

Over the last decades, loss of teeth is increaingly being treated by dental implants. By today more than 100 mill. implants are installed in a large number of patients world wide. Recent years, however, the clinical community has become aware of a signifi cant complication of this treatment: A major fraction of the patients develop an inflammatory condition called peri-implant disease. The most serious version, peri-implantitis, also comprising bone loss and eventually loss of implant, affects double digit number percentage of patients. The precursor, involving only soft tissue inflammation, may affect more than half the patients. This is a significant problem, affecting in the range of 25-50 mill. patients. Containment and treatment of the condition relie s overwhelmingly on practices and devices from tradtional dentistry, and does not take into account the unique challenges foreign bodies as metal implants in bones poses. Accordingly, there is limited succes with these current treatement regimes, and cons iderable frustration in the clinical community. Labrida AS has developed a dedicated device for maintenance treatment of inflamed dental implants, based on deploying bioresorbabale materials in the revision tool. Through this, we eliminate the risk otherw ise run when treating foreign bodies in live bone: That the therapist aggravates the condition by leaving more foreign bodies from the revision tools by the implant, thus spurring stronger inflammation and foreign body reaction. The bioresorbable material is rapidly degraded in the body into harmless molecules. Our first clinical trials indicates clearly that treatment protocols deploying our instrument is easier, faster and better than tradtional treatment protocolls. This project aims at documenting thi s further in a multi-center scientific clinical trial, as well as optimizing the final design of the device.

Funding scheme:

FORNY20-FORNY2020